Dermatide Biotech Showcases AKNETIDE^® at In-Cosmetics Global 2026, Secures Strong European Partnerships

Paris, France – April 2026 – Following a highly successful exhibition at In-Cosmetics Global 2026 in Paris, we are thrilled to announce a significant milestone in our international expansion. Our proprietary bioactive cyclopeptide, AKNETIDE^®, captured substantial attention from leading European distribution partners, validating our commitment to deep tech, science-backed personal care innovations.

Throughout the event, our team had the opportunity to present the robust scientific dataset behind AKNETIDE^®. The strong reception from industry leaders was driven by our comprehensive, placebo-controlled clinical study results, which clearly demonstrate the peptide’s targeted efficacy and safety profile in blemish-care applications.

As a biotechnology innovator focused on next-generation bioactive molecules, we understand that modern personal care formulators demand not just novel ingredients, but irrefutable clinical evidence. The overwhelming interest from influential European distributors confirms that AKNETIDE^®’s rigorous R&D foundation—stemming from our specialized focus on high-performance molecules—is exactly what the global market is seeking.

We are currently advancing discussions with several key European partners to establish a strong distribution network across the EU. These strategic alliances will be instrumental in bringing our advanced biomolecular solutions to a wider audience, empowering formulators to create highly effective, scientifically validated skincare products.

Stay tuned for more updates as we finalize these partnerships and continue to push the boundaries of biotechnology in personal care.